Caprihans India Ltd. (BSE: 509486) is a Pune, Maharashtra-based company in the Plastic and Synthetic Resins industry. With a market capitalisation of ₹164 Cr, it ranks #2,831 by market cap among the 6,137 Indian listed companies on FinBizNet, and #34 of 63 in Plastic and Synthetic Resins. At ₹86.80 (as of 25 Oct 2026), the share price is 37.5% below its 52-week high of ₹138.85 and 72.6% above its 52-week low of ₹50.30. The share price is down 31.3% over one year and up 13.5% over three months.
| Current Price | ₹86.80 |
|---|---|
| Market Cap | ₹164 Cr |
| BSE Code | 509486 |
| Sector | Materials > Chemicals > Commodity Chemicals |
| Sub-Industry | Commodity Chemicals > Plastic and Synthetic Resins |
| P/E Ratio | -2.9 |
| Return on Equity | -11.25% |
| Return on Assets | -0.16% |
| 52-Week Range | ₹50.30 – ₹138.85 |
| 1-Year Price Change | -31.3% |
| 3-Month Price Change | +13.5% |
| Beta (1Y) | 1.03 |
| Dividend Yield | 0.00% |
| Headquarters | Pune, Maharashtra |
| Website | caprihansindia.com |
Caprihans India Limited engages in the pharmaceutical packaging business in India and internationally. The company also manufactures and sells rigid and flexible polyvinyl chloride (PVC) films, polyvinylidene chloride (PVDC) coated films, plastic extruded products, alu alu foils, and other allied products. In addition, it provides thermoforming blister films under the Duplex, Triplex, Ultra, Ultra Tx, Armour, Aclar, Excel, Exxtra, Optra, BAPP, Zymax, Zymax Tx, and Zymax PDP names; coldforming blister foils under the Venus, Venus PR, Venus SBC, Tropical Foil, Nutra Venus, and Vento Venus names; lidding blister foils under the Zeon, Zeon+, Zenith, Zeon+PR, Suppo Zenith, Zeon PR, Zeon D, Zeon X, and DESALU names; lidding foils under the Crispak AP-PT, Crispak PL, Crispak PP, and Crispak PT names; and laminates/sachet foils under the Lamiflex PAL and RAL brand names. Further, the company offers pharma packaging research services, including formulation stability studies, blister / foil desi
1. Calendered Products-This segment manufactures polyvinyl chloride (PVC) films. It also produces polyvinylidene chloride coated rigid PVC film and other plastic products through extrusion processes. 2. Extruded Products-This segment develops calendered products for new applications like tag application in readymade garments, visual packaging, smart card lamination, and PP sheets for opaque door. 3. Construction/Real Estate-This segment develops extruded products for new applications like tag application in readymade garments, visual packaging, smart card lamination, and PP sheets for opaque door. 4. Trading-This segment is involved in construction and real estate activities.
1. Pharma Packaging Solutions-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Garware Hi-Tech Films Ltd | ₹16,181 Cr | 47.7 | 13.45% | ₹696 Cr | +116.1% |
| Supreme Petrochem Ltd | ₹14,419 Cr | 43.7 | 14.32% | ₹1,715 Cr | -8.1% |
| Finolex Industries Ltd. | ₹9,500 Cr | 15.6 | 9.73% | ₹884 Cr | -25.8% |
| Kingfa Science & Technology Ltd | ₹8,858 Cr | 44.4 | 17.41% | ₹689 Cr | +34.0% |
| Swan Corp Ltd | ₹8,322 Cr | 29.3 | 3.00% | ₹1,014 Cr | -44.2% |
| Kama Holdings Ltd | ₹7,298 Cr | 7.8 | 12.93% | — | — |
| Epigral Ltd | ₹4,296 Cr | 12.7 | 16.09% | ₹705 Cr | -47.4% |
| Responsive Industries Ltd. | ₹4,023 Cr | 26.9 | 10.22% | ₹193 Cr | -22.3% |
| Caprihans India Ltd. | ₹164 Cr | -2.9 | -11.25% | — | -31.3% |
Listed by market capitalisation. Ratios are shown for context only.
Caprihans India Ltd. is trading at ₹86.80, with a market capitalisation of ₹164 Cr.
Caprihans India Ltd. operates in the Materials > Chemicals > Commodity Chemicals space (Commodity Chemicals > Plastic and Synthetic Resins).
Caprihans India Ltd. has a P/E of -2.9 and a return on equity of -11.25%.
Caprihans India Ltd. is listed on the BSE under the scrip code 509486.
Caprihans India Ltd.'s share price is down 31.3% over one year and up 13.5% over three months. Its 52-week range is ₹50.30 to ₹138.85.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.